Related Articles
Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer
Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients
Clinical value of serum tumor markers CA19‑9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma
Preoperative CA19‑9 level and dual time point FDG‑PET/CT as strong biological indicators of borderline resectability in pancreatic cancer: A retrospective study
Neoadjuvant chemotherapy with gemcitabine‑based regimens improves the prognosis of node positive resectable pancreatic head cancer